Evidence map›Paper›PMID 38051154›Full record

ArticleEndocrine connections2024

Clinical significance of CYP11B2 immunostaining in unilateral primary aldosteronism.

Marianna Viukari, Helena Leijon, Tiina Vesterinen, Sanni Söderlund, Päivi Hämäläinen, Iina Yliaska, Päivi Rautiainen, Reeta Rintamäki, Minna Soinio, Ilkka Pörsti and 2 more

Open access · goldAbstract read
In one paragraph

Article in Endocrine connections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Marianna ViukariEndocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0001-9720-5026
Helena LeijonDepartment of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Tiina VesterinenDepartment of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Sanni SöderlundEndocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Päivi HämäläinenDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Iina YliaskaMedical Research Center Oulu, Oulu University Hospital and Research Unit of Internal Medicine, University of Oulu, Oulu, Finland.
Päivi RautiainenJoint Municipal Authority for North Karelia Social and Health Services (Siun Sote), Joensuu, Finland.
Reeta RintamäkiDepartment of Endocrinology and Clinical Nutrition, Kuopio University Hospital, Kuopio, Finland.
Minna SoinioDepartment of Endocrinology, Turku University Hospital, Turku, Finland.
Ilkka PörstiDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Pasi I NevalainenDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland.ORCID 0000-0002-7397-6122
Niina MatikainenEndocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-0041-1240
University of Helsinki · FITampere University Hospital · FIKuopio University Hospital · FINorth Karelia Central Hospital · FIOulu University Hospital · FITampere University · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The associations between adrenal histopathology, lateralization studies, and surgical outcomes in primary aldosteronism remain poorly characterized. We examined the value of immunohistochemical analysis of CYP11B2 for evaluation of adrenalectomy outcomes after anatomical versus functional subtyping. Design: A retrospective multicenter study of 277 patients operated for primary aldosteronism who had an adrenalectomy sample available in the Finnish biobanks from 1 January 2000 to 31 December 2019. Adrenal slides from biobanks were analyzed centrally after CYP11B2 and CYP11B1 staining. Clinical data were obtained from patient registries. Histopathological diagnosis and cure after surgery were assessed as outcome measures. Results: Re-evaluation with CYP11B2 staining changed the histopathological diagnosis in 91 patients (33%). The presence of a CYP11B2-positive adenoma and the use of functional subtyping independently predicted clinical cure of primary aldosteronism. CYP11B2-positive <7 mm nodules were more frequent in patients without clinical cure, whereas CYP11B2-positive micronodules were common in all patients and had no impact on adrenalectomy outcomes. Small CYP11B2-positive nodules and micronodules were equally prevalent regardless of the subtyping method applied. Clinical cure rates were lower and CYP11B2-negative adenomas more common after adrenalectomy based on anatomical imaging than functional studies. Conclusions: Incorporating CYP11B2 staining in histopathological diagnosis enhances the prediction of surgical outcomes in primary aldosteronism. A finding of CYP11B2-positive adenoma is indicative of cure of primary aldosteronism, whereas smaller CYP11B2-positive nodules associate with poorer results at postoperative evaluation. Functional subtyping methods decrease the operations of CYP11B2-negative adenomas and are superior to anatomical imaging in identifying unilateral primary aldosteronism.

Indexed as

adrenalectomy outcomeadrenal venous samplingCYP11B2 immunostainingfunctional subtypingprimary aldosteronism

Identifiers

PMID38051154
PMCPMC10831582
OpenAlexW4389335673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.